Australian regenerative medicine company Mesoblast (ASX: MSB) is continuing with a Phase III trial of remestemcel-L in people with moderate to severe acute respiratory distress syndrome (ARDS).
The decision follows a recommendation to continue from the independent Data Safety Monitoring Board (DSMB), after the trial’s second interim analysis.
The DSMB looked at data from the first 135 patients, 45% of the total target of up to 300, in respect of the primary endpoint, all-cause mortality within 30 days of randomization.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze